We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$71.3B
1-Year Est. Return
56.8%
This Fund
S&P 500
This Quarter
Est. Return
+24.89%
1 Year Est. Return
+56.8%
3 Year Est. Return
+170.28%
5 Year Est. Return
+249.16%
10 Year Est. Return
+1,007.9%
AUM
$71.3B
AUM Growth
+$6.48B
(+10%)
Cap. Flow
-$2.43B
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
29.48%
Holding
1,130
New
174
Increased
291
Reduced
392
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Devon Energy
DVN
|
+$353M |
| 2 |
Marvell Technology
MRVL
|
+$150M |
| 3 |
Spyre Therapeutics
SYRE
|
+$126M |
| 4 |
BridgeBio Pharma
BBIO
|
+$116M |
| 5 |
Dover
DOV
|
+$110M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$713M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$355M |
| 3 |
CTRA
Coterra Energy
CTRA
|
+$289M |
| 4 |
Royalty Pharma
RPRX
|
+$259M |
| 5 |
Eli Lilly
LLY
|
+$236M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.29% |
| 2 | Healthcare | 14.03% |
| 3 | Financials | 12.39% |
| 4 | Industrials | 8.94% |
| 5 | Communication Services | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
776
HealthEquity
HQY
$7.66B
| $6.86M | 0.01% |
76,000
-21,000
| -22% | -$1.78M |
|
777
Gartner
IT
$10.7B
| $6.83M | 0.01% |
52,700
+11,800
| +29% | +$1.78M |
|
778
Artesian Resources
ARTNA
$377M
| $6.8M | 0.01% |
200,000
| – | – |
|
779
Acadia Healthcare
ACHC
$2.62B
| $6.8M | 0.01% |
+230,140
| New | +$5.91M |
|
780
Skyworks Solutions
SWKS
$11.5B
| $6.72M | 0.01% |
+99,050
| New | +$6.74M |
|
781
LKQ Corp
LKQ
$6.12B
| $6.4M | 0.01% |
243,113
-6,897
| -3% | -$192K |
|
782
Lifezone Metals
LZM
$363M
| $6.37M | 0.01% |
1,642,238
-146,057
| -8% | -$682K |
|
783
Factset
FDS
$9.93B
| $6.33M | 0.01% |
27,500
+25,400
| +1,210% | +$5.83M |
|
784
Seacoast Banking Corp of Florida
SBCF
$3.28B
| $6.3M | 0.01% |
+189,340
| New | +$5.91M |
|
|
RAPP
785
Rapport Therapeutics
RAPP
$2.11B
| $6.25M | 0.01% |
150,000
| – | – |
|
|
ANL
786
Adlai Nortye Group ADS
ANL
$946M
| $6.19M | 0.01% |
538,461
| – | – |
|
787
Baxter International
BAX
$12.6B
| $6.15M | 0.01% |
+288,347
| New | +$5.37M |
|
788
Evercore
EVR
$11.1B
| $6.15M | 0.01% |
18,000
-71,900
| -80% | -$24.6M |
|
|
ITHA
789
ITHAX Acquisition Corp III
ITHA
$308M
| $5.99M | 0.01% |
600,000
| – | – |
|
790
Carlyle Group
CG
$15.7B
| $5.9M | 0.01% |
140,100
+130,199
| +1,315% | +$6.12M |
|
791
Bank of N.T. Butterfield & Son
NTB
$2.35B
| $5.84M | 0.01% |
98,074
-112,980
| -54% | -$6.39M |
|
792
ZIM Integrated Shipping Services
ZIM
$3.54B
| $5.73M | 0.01% |
+220,214
| New | +$5.68M |
|
793
Brighthouse Financial
BHF
$2.94B
| $5.7M | 0.01% |
90,111
-125,000
| -58% | -$7.77M |
|
|
FCBM
794
First Carolina Financial Services
FCBM
$392M
| $5.63M | 0.01% |
+425,000
| New | +$5.45M |
|
795
Molson Coors Class B
TAP
$7.17B
| $5.57M | 0.01% |
142,936
-8,100
| -5% | -$338K |
|
796
Ingersoll Rand
IR
$28.5B
| $5.53M | 0.01% |
67,392
-101,500
| -60% | -$7.85M |
|
|
NP
797
Neptune Insurance Holdings
NP
$4.34B
| $5.51M | 0.01% |
175,000
-125,000
| -42% | -$3.39M |
|
|
OKUR
798
OnKure Therapeutics
OKUR
$137M
| $5.49M | 0.01% |
1,204,819
| – | – |
|
|
SW
799
Smurfit Westrock
SW
$22.1B
| $5.43M | 0.01% |
117,389
-23,700
| -17% | -$979K |
|
800
Lamb Weston
LW
$6.62B
| $5.41M | 0.01% |
125,256
+25,256
| +25% | +$1.09M |
|
Similar funds
Adage Capital Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Adage Capital Partners held 1,130 positions worth $71.3B, up 10% from $64.8B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Adage Capital Partners withdrew a net $2.43B in Q2 2026, closing 128 positions and reducing 392 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $355M position sold in full.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 27% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Marvell Technology worth $222M.
- Adage Capital Partners's largest Q2 2026 buy was Marvell Technology: 745,800 shares worth $222M.
- Adage Capital Partners added most to Devon Energy in Q2 2026, an estimated $353M increase.
- Adage Capital Partners's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $713M.
- Adage Capital Partners fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $355M.
- Adage Capital Partners's ten largest holdings make up 29% of its $71.3B portfolio in Q2 2026.
- Adage Capital Partners opened 174 new positions and closed 128 in Q2 2026.
- Adage Capital Partners's portfolio value rose 10% quarter-over-quarter to $71.3B.
Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.